NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 4,910 Shares of Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 4,910 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $6.66, for a total value of $32,700.60. Following the completion of the sale, the insider now owns 5,540,104 shares of the company’s stock, valued at $36,897,092.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total value of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The shares were sold at an average price of $6.54, for a total value of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The stock was sold at an average price of $6.35, for a total transaction of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total transaction of $19,050.30.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The stock was sold at an average price of $6.97, for a total transaction of $23,126.46.

NeuroPace Price Performance

Shares of NASDAQ:NPCE opened at $6.47 on Friday. The company has a market cap of $186.13 million, a P/E ratio of -5.44 and a beta of 1.78. The company’s fifty day moving average is $7.05 and its two-hundred day moving average is $8.41. The company has a quick ratio of 5.47, a current ratio of 6.37 and a debt-to-equity ratio of 5.97. NeuroPace, Inc. has a 12-month low of $5.73 and a 12-month high of $18.15.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.03. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The firm had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. During the same period in the prior year, the business earned ($0.36) EPS. The business’s revenue for the quarter was up 16.6% on a year-over-year basis. Equities analysts expect that NeuroPace, Inc. will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on NPCE shares. Morgan Stanley decreased their price target on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Wells Fargo & Company cut their target price on NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Institutional Trading of NeuroPace

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers acquired a new position in NeuroPace in the 2nd quarter valued at approximately $111,000. Financial Advocates Investment Management grew its holdings in shares of NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after acquiring an additional 5,000 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new position in shares of NeuroPace in the first quarter worth $155,000. XTX Topco Ltd raised its holdings in shares of NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after acquiring an additional 8,643 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of NeuroPace during the 2nd quarter worth about $257,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.